Korean Firms Readying To Compete In Global GLP-1 Obesity Space
Hanmi Leading With Phase III Trial
With Hanmi's progress in changing the main indication of its GLP-1 contender efpeglenatide to obesity, Scrip takes an infographic look at what other Korean firms are doing in both this indication and elsewhere in the GLP-1 space.
You may also be interested in...
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
South Korean firm AriBio is planning to expand global Phase III trials for its oral Alzheimer’s disease candidate following an IND approval at home. Patient enrolment in a US trial began late last year.
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.